# Daniel Birnbaum

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 217 papers | 19,077 citations | 69 h-index | 136 g-index |
| 237 ext. papers | 21,585 ext. citations | 7.9 avg, IF | 5.98 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 217 | Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC.. *Npj Breast Cancer*, **2022**, 8, 12 | 7.8 | 0 |
| 216 | BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells.. *Cell Death and Disease*, **2022**, 13, 96 | 9.8 | 1 |
| 215 | Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy. *Journal of Personalized Medicine*, **2022**, 12, 655 | 3.6 | 0 |
| 214 | TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients. *European Journal of Cancer*, **2021**, 159, 205-214 | 7.5 | 0 |
| 213 | EFA6B regulates a stop signal for collective invasion in breast cancer. *Nature Communications*, **2021**, 12, 2198 | 17.4 | 1 |
| 212 | Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. *Genome Medicine*, **2021**, 13, 87 | 14.4 | 8 |
| 211 | The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer. *Npj Breast Cancer*, **2021**, 7, 48 | 7.8 | 0 |
| 210 | WEE1 Dependency and Pejorative Prognostic Value in Triple-Negative Breast Cancer. *Advanced Science*, **2021**, 8, e2101030 | 13.6 | 3 |
| 209 | Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma. *Clinical Cancer Research* , **2021**, 27, 2314-2325 | 12.9 | 3 |
| 208 | Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. *OncoImmunology*, **2021**, 10, 1929724 | 7.2 | 4 |
| 207 | SLX4 interacts with RTEL1 to prevent transcription-mediated DNA replication perturbations. *Nature Structural and Molecular Biology*, **2020**, 27, 438-449 | 17.6 | 16 |
| 206 | A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study. *Blood Cancer Journal*, **2020**, 10, 64 | 7 | 6 |
| 205 | Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. *Blood*, **2020**, 136, 698-714 | 2.2 | 16 |
| 204 | EBV+ diffuse large B-cell lymphoma associated with chronic inflammation expands the spectrum of breast implant-related lymphomas. *Blood*, **2020**, 135, 2004-2009 | 2.2 | 6 |
| 203 | The therapeutic response of ER+/HER2- breast cancers differs according to the molecular Basal or Luminal subtype. *Npj Breast Cancer*, **2020**, 6, 8 | 7.8 | 14 |
| 202 | Adolescents and young adults with classical Hodgkin lymphoma in northern Tunisia: insights from an adult single-institutional study. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique*, **2020**, 24, 206-214 | 1.3 | 1 |
| 201 | Gains of EPOR and ERG genes in adult erythroleukaemia. *British Journal of Haematology*, **2020**, 189, e174–e177 | 4.8 | 3 |

| | | | |
|---|---|---|---|
| 200 | ERBB2b mRNA isoform encodes a nuclear variant of the ERBB2 oncogene in breast cancer. *Journal of Cellular Biochemistry*, **2020**, 121, 4870 | 4.7 | |
| 199 | Overexpression of Annexin A1 Is an Independent Predictor of Longer Overall Survival in Epithelial Ovarian Cancer. *In Vivo*, **2020**, 34, 177-184 | 2.3 | 6 |
| 198 | NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. *Molecular Oncology*, **2020**, 14, 504-519 | 7.9 | 13 |
| 197 | Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer-Letter. *Clinical Cancer Research*, **2020**, 26, 5539 | 12.9 | |
| 196 | Acute erythroid leukemias have a distinct molecular hierarchy from non-erythroid acute myeloid leukemias. *Haematologica*, **2020**, 105, e340-e342 | 6.6 | 2 |
| 195 | Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins?. *Cancers*, **2020**, 12, | 6.6 | 5 |
| 194 | Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease. *Cancers*, **2019**, 11, | 6.6 | 12 |
| 193 | PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target. *Molecular Oncology*, **2019**, 13, 1577-1588 | 7.9 | 14 |
| 192 | Genomic characterization of metastatic breast cancers. *Nature*, **2019**, 569, 560-564 | 50.4 | 256 |
| 191 | Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma. *Journal of Clinical Medicine*, **2019**, 8, | 5.1 | 9 |
| 190 | A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases. *Cancers*, **2019**, 11, | 6.6 | 17 |
| 189 | Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors. *Cancers*, **2019**, 11, | 6.6 | 35 |
| 188 | ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer. *British Journal of Cancer*, **2019**, 120, 931-940 | 8.7 | 7 |
| 187 | A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers. *Cancers*, **2019**, 11, | 6.6 | 1 |
| 186 | Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation. *Clinical Epigenetics*, **2019**, 11, 141 | 7.7 | 4 |
| 185 | A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells. *EMBO Molecular Medicine*, **2019**, 11, e9930 | 12 | 12 |
| 184 | Sensitive and easy screening for circulating tumor cells by flow cytometry. *JCI Insight*, **2019**, 5, | 9.9 | 16 |
| 183 | High Response to Cetuximab in a Patient With -Amplified Heavily Pretreated Metastatic Triple-Negative Breast Cancer.. *JCO Precision Oncology*, **2019**, 3, 1-8 | 3.6 | 1 |

| | | | |
|---|---|---|---|
| 182 | JAK-STAT PATHWAY AND EPIGENETIC REGULATORS ARE CRITICAL PLAYERS IN BI-ALCL PATHOGENESIS?. *Hematological Oncology*, **2019**, 37, 201-201 | 1.3 | |
| 181 | MARCKS protein overexpression is associated with poor prognosis in male breast cancer. *Cancer Biomarkers*, **2019**, 26, 513-522 | 3.8 | 4 |
| 180 | Major Response to Carboplatin in a Patient With Metastatic Triple-Negative Breast Cancer With Somatic Mutation of and Loss of .. *JCO Precision Oncology*, **2019**, 3, 1-9 | 3.6 | |
| 179 | Pathological grade-independent prediction of chemosensitivity by CINSARC should rehabilitate adjuvant chemotherapy in soft tissue sarcomas of any grade. *Annals of Oncology*, **2019**, 30, 342-343 | 10.3 | 1 |
| 178 | Mutation patterns in essential thrombocythemia, polycythemia vera and secondary myelofibrosis. *Leukemia and Lymphoma*, **2019**, 60, 1289-1293 | 1.9 | 2 |
| 177 | Targeted molecular characterization shows differences between primary and secondary myelofibrosis. *Genes Chromosomes and Cancer*, **2019**, 59, 30 | 5 | 7 |
| 176 | Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2018**, 1869, 248-255 | 11.2 | 16 |
| 175 | "Wnt/Catenin in GIST"-Letter. *Molecular Cancer Therapeutics*, **2018**, 17, 327-328 | 6.1 | 4 |
| 174 | The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma. *Annals of Oncology*, **2018**, 29, 459-465 | 10.3 | 16 |
| 173 | Mutation of FOP/FGFR1OP in mice recapitulates human short rib-polydactyly ciliopathy. *Human Molecular Genetics*, **2018**, 27, 3377-3391 | 5.6 | 5 |
| 172 | Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms. *American Journal of Hematology*, **2018**, 93, 330-338 | 7.1 | 34 |
| 171 | Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer.. *JCO Precision Oncology*, **2018**, 2, 1-8 | 3.6 | 1 |
| 170 | Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer. *Oncotarget*, **2018**, 9, 33762-33777 | 3.3 | 13 |
| 169 | The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. *British Journal of Cancer*, **2018**, 119, 1383-1391 | 8.7 | 23 |
| 168 | miR-600 Acts as a Bimodal Switch that Regulates Breast Cancer Stem Cell Fate through WNT Signaling. *Cell Reports*, **2017**, 18, 2256-2268 | 10.6 | 81 |
| 167 | A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability. *Nature Medicine*, **2017**, 23, 568-578 | 50.5 | 78 |
| 166 | Salinomycin kills cancer stem cells by sequestering iron in lysosomes. *Nature Chemistry*, **2017**, 9, 1025-1033 | 17.6 | 254 |
| 165 | Prognostic Value of Molecular Subtypes in Pancreatic Cancer. *Pancreas*, **2017**, 46, e29-e31 | 2.6 | 7 |

| | | | |
|---|---|---|---|
| 164 | Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC). *Neoplasia*, **2017**, 19, 564-573 | 6.4 | 15 |
| 163 | Fifteen years of research on oral-facial-digital syndromes: from 1 to 16 causal genes. *Journal of Medical Genetics*, **2017**, 54, 371-380 | 5.8 | 58 |
| 162 | Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. *Annals of Oncology*, **2017**, 28, 769-776 | 10.3 | 32 |
| 161 | Genomic analysis of myeloproliferative neoplasms in chronic and acute phases. *Haematologica*, **2017**, 102, e11-e14 | 6.6 | 29 |
| 160 | Wnt Signaling Inhibition Promotes Apoptosis in Sarcomas-Letter. *Molecular Cancer Therapeutics*, **2017**, 16, 2324 | 6.1 | 2 |
| 159 | A 25-gene classifier predicts overall survival in resectable pancreatic cancer. *BMC Medicine*, **2017**, 15, 170 | 11.4 | 41 |
| 158 | Validation and comparison of the molecular classifications of pancreatic carcinomas. *Molecular Cancer*, **2017**, 16, 168 | 42.1 | 21 |
| 157 | Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value. *International Journal of Molecular Sciences*, **2017**, 19, | 6.3 | 5 |
| 156 | Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification. *Blood Cancer Journal*, **2017**, 7, e594 | 7 | 6 |
| 155 | Flick the cancer stem cells switch to turn cancer off. *Molecular and Cellular Oncology*, **2017**, 4, e1319896 | 1.2 | |
| 154 | MARCKS protein overexpression in inflammatory breast cancer. *Oncotarget*, **2017**, 8, 6246-6257 | 3.3 | 21 |
| 153 | De-repression of the RAC activator ELMO1 in cancer stem cells drives progression of TGF deficient squamous cell carcinoma from transition zones. *ELife*, **2017**, 6, | 8.9 | 9 |
| 152 | Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing. *Leukemia*, **2016**, 30, 966-70 | 10.7 | 25 |
| 151 | A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers. *Nature Communications*, **2016**, 7, 12222 | 17.4 | 77 |
| 150 | SPAG5: the ultimate marker of proliferation in early breast cancer?. *Lancet Oncology, The*, **2016**, 17, 863-865 | 27.4 | 9 |
| 149 | Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2-JNK signalling in breast cancer. *Nature Communications*, **2016**, 7, 10318 | 17.4 | 55 |
| 148 | Breast cancer stem cells programs: enter the (non)-code. *Briefings in Functional Genomics*, **2016**, 15, 186-99 | 4.9 | 5 |
| 147 | OFIP/KIAA0753 forms a complex with OFD1 and FOR20 at pericentriolar satellites and centrosomes and is mutated in one individual with oral-facial-digital syndrome. *Human Molecular Genetics*, **2016**, 25, 497-513 | 5.6 | 30 |

| | | | |
|---|---|---|---|
| 146 | Prognostic value of PDL1 expression in pancreatic cancer. *Oncotarget*, **2016**, 7, 71198-71210 | 3.3 | 59 |
| 145 | Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. *Oncotarget*, **2016**, 7, 79428-79441 | 3.3 | 8 |
| 144 | MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. *Oncotarget*, **2016**, 7, 18531-40 | 3.3 | 31 |
| 143 | Comparative genomic analysis of primary tumors and metastases in breast cancer. *Oncotarget*, **2016**, 7, 27208-19 | 3.3 | 53 |
| 142 | Epigenetically centered evolution in an example of myeloid malignancy. *American Journal of Hematology*, **2016**, 91, E361-2 | 7.1 | |
| 141 | A phenotypic and mechanistic perspective on heterogeneity of HER2-positive breast cancers. *Molecular and Cellular Oncology*, **2016**, 3, e1232186 | 1.2 | 2 |
| 140 | PRICKLE1 Contributes to Cancer Cell Dissemination through Its Interaction with mTORC2. *Developmental Cell*, **2016**, 37, 311-325 | 10.2 | 32 |
| 139 | Mutational analysis of the DOK2 haploinsufficient tumor suppressor gene in chronic myelomonocytic leukemia (CMML). *Leukemia*, **2015**, 29, 500-2 | 10.7 | 9 |
| 138 | Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. *Breast Cancer Research and Treatment*, **2015**, 154, 495-508 | 4.4 | 40 |
| 137 | Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer. *Journal of Translational Medicine*, **2015**, 13, 138 | 8.5 | 32 |
| 136 | Prognostic and predictive value of PDL1 expression in breast cancer. *Oncotarget*, **2015**, 6, 5449-64 | 3.3 | 313 |
| 135 | PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. *Oncotarget*, **2015**, 6, 13506-19 | 3.3 | 87 |
| 134 | Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia. *Blood Cancer Journal*, **2015**, 5, e292 | 7 | 18 |
| 133 | Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. *Oncotarget*, **2015**, 6, 8388-96 | 3.3 | 52 |
| 132 | Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. *Annals of Oncology*, **2014**, 25, 358-65 | 10.3 | 65 |
| 131 | Brief reports: A distinct DNA methylation signature defines breast cancer stem cells and predicts cancer outcome. *Stem Cells*, **2014**, 32, 3031-6 | 5.8 | 24 |
| 130 | ESPL1 is a candidate oncogene of luminal B breast cancers. *Breast Cancer Research and Treatment*, **2014**, 147, 51-9 | 4.4 | 31 |
| 129 | Genomic profiling of inflammatory breast cancer: a review. *Breast*, **2014**, 23, 538-45 | 3.6 | 40 |

| | | | |
|---|---|---|---|
| 128 | Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. *Stem Cell Reports*, **2014**, 2, 78-91 | 8 | 656 |
| 127 | Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase. *Haematologica*, **2014**, 99, 37-45 | 6.6 | 34 |
| 126 | Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib. *PLoS ONE*, **2014**, 9, e104302 | 3.7 | 35 |
| 125 | Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling. *PLoS ONE*, **2014**, 9, e81843 | 3.7 | 42 |
| 124 | The functional landscape of Hsp27 reveals new cellular processes such as DNA repair and alternative splicing and proposes novel anticancer targets. *Molecular and Cellular Proteomics*, **2014**, 13, 3585-601 | 7.6 | 35 |
| 123 | EFA6B antagonizes breast cancer. *Cancer Research*, **2014**, 74, 5493-506 | 10.1 | 16 |
| 122 | Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia. *American Journal of Hematology*, **2014**, 89, 604-9 | 7.1 | 32 |
| 121 | Signaling pathway switch in breast cancer. *Cancer Cell International*, **2013**, 13, 66 | 6.4 | 22 |
| 120 | ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. *Cancer Research*, **2013**, 73, 7290-300 | 10.1 | 98 |
| 119 | Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets. *Journal of Immunology*, **2013**, 190, 2424-36 | 5.3 | 69 |
| 118 | Prognostic score including gene mutations in chronic myelomonocytic leukemia. *Journal of Clinical Oncology*, **2013**, 31, 2428-36 | 2.2 | 373 |
| 117 | Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. *Clinical Cancer Research*, **2013**, 19, 4685-96 | 12.9 | 99 |
| 116 | SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. *Leukemia*, **2013**, 27, 1401-3 | 10.7 | 88 |
| 115 | The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression. *Clinical Cancer Research*, **2013**, 19, 6520-31 | 12.9 | 112 |
| 114 | Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients. *Annals of Oncology*, **2013**, 24, 625-32 | 10.3 | 26 |
| 113 | Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts. *Haematologica*, **2013**, 98, 576-83 | 6.6 | 9 |
| 112 | BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. *Blood*, **2013**, 122, 3169-77 | 2.2 | 147 |
| 111 | Gene expression profiling of solitary fibrous tumors. *PLoS ONE*, **2013**, 8, e64497 | 3.7 | 13 |

| | | | |
|---|---|---|---|
| 110 | Mutations and deletions of ARID1A in breast tumors. *Oncogene*, **2012**, 31, 4255-6 | 9.2 | 47 |
| 109 | Cellules souches du cancer du sein : prendre le cancer la racine. *Oncologie*, **2012**, 14, 543-549 | 1 | |
| 108 | Myeloid malignancies: mutations, models and management. *BMC Cancer*, **2012**, 12, 304 | 4.8 | 101 |
| 107 | A refined molecular taxonomy of breast cancer. *Oncogene*, **2012**, 31, 1196-206 | 9.2 | 190 |
| 106 | 8q24 Cancer risk allele associated with major metastatic risk in inflammatory breast cancer. *PLoS ONE*, **2012**, 7, e37943 | 3.7 | 27 |
| 105 | Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer. *PLoS ONE*, **2012**, 7, e43409 | 3.7 | 2 |
| 104 | Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target. *Stem Cells*, **2012**, 30, 1327-37 | 5.8 | 97 |
| 103 | Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. *Blood*, **2012**, 119, 3211-8 | 2.2 | 188 |
| 102 | Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. *Journal of Hematology and Oncology*, **2012**, 5, 12 | 22.4 | 187 |
| 101 | What drives breast cancer heterogeneity: oncogenic events or cell of origin?. *Journal of Pathology*, **2012**, 227, 267-9 | 9.4 | 1 |
| 100 | Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. *Genes Chromosomes and Cancer*, **2012**, 51, 743-55 | 5 | 119 |
| 99 | Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents. *Breast Cancer Research and Treatment*, **2012**, 132, 1035-47 | 4.4 | 12 |
| 98 | MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. *PLoS Genetics*, **2012**, 8, e1002751 | 6 | 136 |
| 97 | The emerging role of the TGF tumor suppressor pathway in pancreatic cancer. *Cell Cycle*, **2012**, 11, 683-6 | 4.7 | 11 |
| 96 | Alterations of polycomb gene BMI1 in human myeloproliferative neoplasms. *Cell Cycle*, **2012**, 11, 3141-2 | 4.7 | 4 |
| 95 | "Stealth" tumors: Breast cancer cells shun NK-cells anti-tumor immunity. *OncoImmunology*, **2012**, 1, 366-368 | 7.2 | 13 |
| 94 | Genomic Grade Index predicts postoperative clinical outcome of GIST. *British Journal of Cancer*, **2012**, 107, 1433-41 | 8.7 | 13 |
| 93 | Basal breast cancer: a complex and deadly molecular subtype. *Current Molecular Medicine*, **2012**, 12, 96-110 | 2.9 | 139 |

| | | | |
|---|---|---|---|
| 92 | Angiogenesis and Lymphangiogenesis in IBC: Insights from a Genome-Wide Gene Expression Profiling Study **2012**, 225-242 | | |
| 91 | Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial. *Breast Cancer Research*, **2011**, 13, R109 | 8.3 | 18 |
| 90 | Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth. *Oncogene*, **2011**, 30, 3862-74 | 9.2 | 40 |
| 89 | Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. *Cancer Research*, **2011**, 71, 6621-32 | 10.1 | 91 |
| 88 | A gene expression signature identifies two prognostic subgroups of basal breast cancer. *Breast Cancer Research and Treatment*, **2011**, 126, 407-20 | 4.4 | 192 |
| 87 | Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. *Breast Cancer Research and Treatment*, **2011**, 127, 363-73 | 4.4 | 7 |
| 86 | Kinome expression profiling and prognosis of basal breast cancers. *Molecular Cancer*, **2011**, 10, 86 | 42.1 | 40 |
| 85 | ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. *EMBO Molecular Medicine*, **2011**, 3, 153-66 | 12 | 88 |
| 84 | Genome profiling of pancreatic adenocarcinoma. *Genes Chromosomes and Cancer*, **2011**, 50, 456-65 | 5 | 98 |
| 83 | Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms. *Blood Cancer Journal*, **2011**, 1, e33 | 7 | 33 |
| 82 | Endometriosis-associated ovarian carcinomas. *New England Journal of Medicine*, **2011**, 364, 483-4; author reply 484-5 | 59.2 | 13 |
| 81 | Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes. *Blood Cancer Journal*, **2011**, 1, e18 | 7 | 14 |
| 80 | Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. *Journal of Clinical Investigation*, **2011**, 121, 3609-22 | 15.9 | 391 |
| 79 | High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes. *PLoS ONE*, **2011**, 6, e16950 | 3.7 | 50 |
| 78 | Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer. *PLoS ONE*, **2011**, 6, e27656 | 3.7 | 108 |
| 77 | ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. *British Journal of Haematology*, **2010**, 151, 365-75 | 4.5 | 175 |
| 76 | Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. *Leukemia*, **2010**, 24, 469-73 | 10.7 | 93 |
| 75 | Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies. *Leukemia*, **2010**, 24, 1539-41 | 10.7 | 6 |

| | | | |
|---|---|---|---|
| 74 | Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. *Leukemia*, **2010**, 24, 1094-6 | 10.7 | 201 |
| 73 | Control of ciliogenesis by FOR20, a novel centrosome and pericentriolar satellite protein. *Journal of Cell Science*, **2010**, 123, 2391-401 | 5.3 | 46 |
| 72 | Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. *Clinical Cancer Research*, **2010**, 16, 45-55 | 12.9 | 570 |
| 71 | The CINSARC signature: prognostic and predictive of response to chemotherapy?. *Cell Cycle*, **2010**, 9, 4025-7 | 4.7 | 9 |
| 70 | Targeting breast cancer stem cells: fishing season open!. *Breast Cancer Research*, **2010**, 12, 312 | 8.3 | 9 |
| 69 | Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. *BMC Cancer*, **2010**, 10, 401 | 4.8 | 125 |
| 68 | Genome profiling of ERBB2-amplified breast cancers. *BMC Cancer*, **2010**, 10, 539 | 4.8 | 114 |
| 67 | Gene expression profiling of inflammatory breast cancer. *Cancer*, **2010**, 116, 2783-93 | 6.4 | 42 |
| 66 | Alteration of cohesin genes in myeloid diseases. *American Journal of Hematology*, **2010**, 85, 717-9 | 7.1 | 44 |
| 65 | CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. *Journal of Clinical Investigation*, **2010**, 120, 485-97 | 15.9 | 577 |
| 64 | TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. *Haematologica*, **2009**, 94, 1676-81 | 6.6 | 198 |
| 63 | A negative feedback regulatory loop associates the tyrosine kinase receptor ERBB2 and the transcription factor GATA4 in breast cancer cells. *Molecular Cancer Research*, **2009**, 7, 402-14 | 6.6 | 24 |
| 62 | Retinoid signaling regulates breast cancer stem cell differentiation. *Cell Cycle*, **2009**, 8, 3297-302 | 4.7 | 168 |
| 61 | The centrosomal FOP protein is required for cell cycle progression and survival. *Cell Cycle*, **2009**, 8, 1217-27 | 4.7 | 22 |
| 60 | Breast cancer stem cells: tools and models to rely on. *BMC Cancer*, **2009**, 9, 202 | 4.8 | 94 |
| 59 | How different are luminal A and basal breast cancers?. *International Journal of Cancer*, **2009**, 124, 1338-48 | 7.5 | 46 |
| 58 | A reason why the ERBB2 gene is amplified and not mutated in breast cancer. *Cancer Cell International*, **2009**, 9, 5 | 6.4 | 10 |
| 57 | Distant metastasis: not out of reach any more. *Journal of Biology*, **2009**, 8, 28 | | 10 |

| | | | |
|---|---|---|---|
| 56 | Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. *British Journal of Haematology*, **2009**, 145, 788-800 | 4.5 | 460 |
| 55 | Alterations of NFIA in chronic malignant myeloid diseases. *Leukemia*, **2009**, 23, 583-5 | 10.7 | 16 |
| 54 | Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases. *Leukemia*, **2009**, 23, 85-94 | 10.7 | 42 |
| 53 | Mutations of ASXL1 gene in myeloproliferative neoplasms. *Leukemia*, **2009**, 23, 2183-6 | 10.7 | 260 |
| 52 | Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. *Cancer Research*, **2009**, 69, 1302-13 | 10.1 | 938 |
| 51 | Ajuba: a new microtubule-associated protein that interacts with BUBR1 and Aurora B at kinetochores in metaphase. *Biology of the Cell*, **2009**, 101, 221-35 | 3.5 | 15 |
| 50 | Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. *Breast Cancer Research*, **2009**, 11, R23 | 8.3 | 65 |
| 49 | TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). *Blood*, **2009**, 114, 3285-91 | 2.2 | 231 |
| 48 | Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogEEique hEmatologique. *Leukemia*, **2008**, 22, 1567-75 | 10.7 | 53 |
| 47 | Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. *Oncogene*, **2008**, 27, 5359-72 | 9.2 | 94 |
| 46 | NCOA3, a new fusion partner for MOZ/MYST3 in M5 acute myeloid leukemia. *Leukemia*, **2008**, 22, 663-5 | 10.7 | 44 |
| 45 | Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. *BMC Cancer*, **2008**, 8, 299 | 4.8 | 102 |
| 44 | Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. *Cancer Research*, **2008**, 68, 767-76 | 10.1 | 86 |
| 43 | Cancer stem cells in breast: current opinion and future challenges. *Pathobiology*, **2008**, 75, 75-84 | 3.6 | 142 |
| 42 | Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. *Molecular and Cellular Proteomics*, **2008**, 7, 1420-33 | 7.6 | 62 |
| 41 | Reasons for breast cancer heterogeneity. *Journal of Biology*, **2008**, 7, 6 | | 57 |
| 40 | How basal are triple-negative breast cancers?. *International Journal of Cancer*, **2008**, 123, 236-40 | 7.5 | 336 |
| 39 | Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. *Oncogene*, **2007**, 26, 298-307 | 9.2 | 71 |

| | | | |
|---|---|---|---|
| 38 | Gene expression profiling separates chronic myelomonocytic leukemia in two molecular subtypes. *Leukemia*, **2007**, 21, 2359-62 | 10.7 | 11 |
| 37 | Nectin-4 is a new histological and serological tumor associated marker for breast cancer. *BMC Cancer*, **2007**, 7, 73 | 4.8 | 102 |
| 36 | Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genes. *Cancer Genetics and Cytogenetics*, **2007**, 176, 80-8 | | 25 |
| 35 | Integrated profiling of basal and luminal breast cancers. *Cancer Research*, **2007**, 67, 11565-75 | 10.1 | 232 |
| 34 | New types of MYST3-CBP and CBP-MYST3 fusion transcripts in t(8;16)(p11;p13) acute myeloid leukemias. *Haematologica*, **2007**, 92, 262-3 | 6.6 | 10 |
| 33 | ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. *Cell Stem Cell*, **2007**, 1, 555-67 | 18 | 3079 |
| 32 | Breast cancer genomics: real-time use. *Lancet Oncology, The*, **2007**, 8, 1045-1047 | 21.7 | 2 |
| 31 | Prognosis and gene expression profiling of 20q13-amplified breast cancers. *Clinical Cancer Research* , **2006**, 12, 4533-44 | 12.9 | 104 |
| 30 | Proteomics of breast cancer: principles and potential clinical applications. *Molecular and Cellular Proteomics*, **2006**, 5, 1772-86 | 7.6 | 58 |
| 29 | Gene expression profiling and clinical outcome in breast cancer. *OMICS A Journal of Integrative Biology*, **2006**, 10, 429-43 | 3.8 | 47 |
| 28 | Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. *Cancer Research*, **2006**, 66, 4636-44 | 10.1 | 235 |
| 27 | Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. *Oncogene*, **2006**, 25, 981-9 | 9.2 | 102 |
| 26 | Gene expression profiling of breast cell lines identifies potential new basal markers. *Oncogene*, **2006**, 25, 2273-84 | 9.2 | 425 |
| 25 | How to best classify breast cancer: Conventional and novel classifications (Review) **2005**, 27, 1307 | | 3 |
| 24 | Multicolour-banding fluorescence in situ hybridisation (mbanding-FISH) to identify recurrent chromosomal alterations in breast tumour cell lines. *British Journal of Cancer*, **2005**, 92, 382-8 | 8.7 | 7 |
| 23 | Comprehensive profiling of 8p11-12 amplification in breast cancer. *Molecular Cancer Research*, **2005** , 3, 655-67 | 6.6 | 178 |
| 22 | Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. *Cancer Research*, **2005**, 65, 2170-8 | 10.1 | 186 |
| 21 | Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. *Cancer Research*, **2005**, 65, 767-79 | 10.1 | 141 |

| | | | |
|---|---|---|---|
| 20 | Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. *Cancer Research*, **2004**, 64, 8558-65 | 10.1 | 155 |
| 19 | A recurrent chromosome breakpoint in breast cancer at the NRG1/neuregulin 1/heregulin gene. *Cancer Research*, **2004**, 64, 6840-4 | 10.1 | 170 |
| 18 | Variant MYST4-CBP gene fusion in a t(10;16) acute myeloid leukaemia. *British Journal of Haematology*, **2004**, 125, 601-4 | 4.5 | 19 |
| 17 | Identification and validation of an ERBB2 gene expression signature in breast cancers. *Oncogene*, **2004**, 23, 2564-75 | 9.2 | 101 |
| 16 | Aurora B -TACC1 protein complex in cytokinesis. *Oncogene*, **2004**, 23, 4516-22 | 9.2 | 41 |
| 15 | Immunophenotypic analysis of inflammatory breast cancers: identification of an inflammatory signature*Journal of Pathology*, **2004**, 202, 265-73 | 9.4 | 150 |
| 14 | A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene. *Genes Chromosomes and Cancer*, **2003**, 37, 333-45 | 5 | 46 |
| 13 | TACC1-chTOG-Aurora A protein complex in breast cancer. *Oncogene*, **2003**, 22, 8102-16 | 9.2 | 81 |
| 12 | Chromosome arm 8p and cancer: a fragile hypothesis. *Lancet Oncology, The*, **2003**, 4, 639-42 | 21.7 | 49 |
| 11 | A further case of acute myelomonocytic leukemia with inv(8) chromosomal rearrangement and MOZ-NCOA2 gene fusion. *International Journal of Molecular Medicine*, **2003**, 12, 423-8 | 4.4 | 13 |
| 10 | Carcinogenesis and translational controls: TACC1 is down-regulated in human cancers and associates with mRNA regulators. *Oncogene*, **2002**, 21, 5619-30 | 9.2 | 56 |
| 9 | Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. *American Journal of Pathology*, **2002**, 161, 1223-33 | 5.8 | 133 |
| 8 | The ERBB2/HER2 receptor differentially interacts with ERBIN and PICK1 PSD-95/DLG/ZO-1 domain proteins. *Journal of Biological Chemistry*, **2001**, 276, 15256-63 | 5.4 | 74 |
| 7 | Gene expression profiling of cancer by use of DNA arrays: how far from the clinic?. *Lancet Oncology, The*, **2001**, 2, 674-82 | 21.7 | 56 |
| 6 | MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). *Genes Chromosomes and Cancer*, **2000**, 28, 138-44 | 5 | 138 |
| 5 | The t(6;8)(q27;p11) Translocation in a Stem Cell Myeloproliferative Disorder Fuses a Novel Gene, FOP, to Fibroblast Growth Factor Receptor 1. *Blood*, **1999**, 93, 1381-1389 | 2.2 | 173 |
| 4 | A case of inv(8)(p11q24) associated with acute myeloid leukemia involves the MOZ and CBP genes in a masked t(8;16) **1999**, 26, 161-165 | | 22 |
| 3 | Hypothesis: more mutations to cure cancer?. *Oncology Reports*, **1999**, 6, 1189-90 | 3.5 | 2 |

| | | | |
|---|---|---|---|
| 2 | Identification of a YAC spanning the translocation breakpoint t(8;22) associated with acute monocytic leukemia. *Genes Chromosomes and Cancer*, **1996**, 15, 191-4 | 5 | 19 |
| 1 | FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. *Genes Chromosomes and Cancer*, **1993**, 7, 219-26 | 5 | 144 |